Shadi Azizi - Academia.edu (original) (raw)

Papers by Shadi Azizi

Research paper thumbnail of Validation of Persian Multiple Sclerosis quality of life-29 (P-MSQOL-29) questionnaire

Acta Neurologica Belgica

Background Multiple sclerosis (MS) is the most prevalent neurological disease among young adults.... more Background Multiple sclerosis (MS) is the most prevalent neurological disease among young adults. Because of the chronic nature of this disease, it is important to assess quality of life in these patients. The Multiple Sclerosis Quality of Life-29 (MSQOL-29) questionnaire which contains two main scales, Physical Health Composite (PHC) and Mental Health Composite (MHC), has been designed for this goal. The purpose of the present study is to translate and validate a Persian version of MSQOL-29 (P-MSQOL-29). Methods Using the forward-backward translation method, a panel of experts established the content validity of P-MSQOL-29. It was then administered to 100 patients with MS who also completed the Short Form-12 (SF-12) questionnaire. Cronbach's alpha was used to assess the internal consistency of P-MSQOL-29. Spearman's correlation coefficient was used to analyze the concurrent validity when correlating the items of P-MSQOL-29 to SF-12. Results Mean (Standard Deviation) of PHC and MHC for all patients was 51 (16.4), and 58 (23), respectively. Cronbach's alpha was 0.7 for PHC and 0.9 for MHC. Thirty patients completed the questionnaire again after 3-4 weeks, Intraclass Correlation Coeffiecient (ICC) was 0.80 for PHCs and 0.85 for MHCs (both P values < 0.01). A moderate to high correlation was detected between MHC/PHC and the corresponding scales of SF-12 (MHC with Mental Component Score: ρ = 0.55; PHC with Physical Component Score: ρ = 0.77; both P values < 0.01). Conclusion P-MSQOL-29 is a valid and reliable questionnaire and can be used for assessing quality of life in patients with MS.

Research paper thumbnail of Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer

Cochrane Database of Systematic Reviews, 2019

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitor... more Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first-or second-line treatment of advanced gastric and gastro-esophageal junction cancer.

Research paper thumbnail of A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies

International Immunopharmacology

We aimed to evaluate immune-related adverse events occurring in clinical trials of anti-programme... more We aimed to evaluate immune-related adverse events occurring in clinical trials of anti-programmed cell death 1 (PD-1) drugs, compared with control treatments, including chemotherapy, targeted drugs, or placebo. Further we compared the occurrence of immune-related events in patients treated with different anti-PD-1 drugs. Data Sources: Randomized controlled trial (RCT) data were sourced from PubMed, Embase, and the Cochrane Central Register of Controlled Trials combined with clinicaltrials.gov. Methods: Randomized controlled trial of anti-PD-1 drugs compared with control treatments published between January 1, 1970 and March 1,2019, were searched and data on trial patient characteristics, and adverse events extracted, reviewed, and subjected to meta-analysis. Results: Eighteen Randomized controlled trials were included in our study. The Randomized controlled trials compared nivolumab (n ¼ 12), pembrolizumab (n ¼ 6), with chemotherapy (n ¼ 13), targeted drugs (n ¼ 2), or placebo (n ¼ 3). Compared with the control group, the risk of any immune-related adverse events in patients treated with anti-PD-1 drugs was increased (RR, 2.65; 95% confidence interval, 1.84-3.83; P < 0.00001). Of the immune-related adverse events, the risk rates of pneumonitis (

Research paper thumbnail of Validation of Persian Multiple Sclerosis quality of life-29 (P-MSQOL-29) questionnaire

Acta Neurologica Belgica

Background Multiple sclerosis (MS) is the most prevalent neurological disease among young adults.... more Background Multiple sclerosis (MS) is the most prevalent neurological disease among young adults. Because of the chronic nature of this disease, it is important to assess quality of life in these patients. The Multiple Sclerosis Quality of Life-29 (MSQOL-29) questionnaire which contains two main scales, Physical Health Composite (PHC) and Mental Health Composite (MHC), has been designed for this goal. The purpose of the present study is to translate and validate a Persian version of MSQOL-29 (P-MSQOL-29). Methods Using the forward-backward translation method, a panel of experts established the content validity of P-MSQOL-29. It was then administered to 100 patients with MS who also completed the Short Form-12 (SF-12) questionnaire. Cronbach's alpha was used to assess the internal consistency of P-MSQOL-29. Spearman's correlation coefficient was used to analyze the concurrent validity when correlating the items of P-MSQOL-29 to SF-12. Results Mean (Standard Deviation) of PHC and MHC for all patients was 51 (16.4), and 58 (23), respectively. Cronbach's alpha was 0.7 for PHC and 0.9 for MHC. Thirty patients completed the questionnaire again after 3-4 weeks, Intraclass Correlation Coeffiecient (ICC) was 0.80 for PHCs and 0.85 for MHCs (both P values < 0.01). A moderate to high correlation was detected between MHC/PHC and the corresponding scales of SF-12 (MHC with Mental Component Score: ρ = 0.55; PHC with Physical Component Score: ρ = 0.77; both P values < 0.01). Conclusion P-MSQOL-29 is a valid and reliable questionnaire and can be used for assessing quality of life in patients with MS.

Research paper thumbnail of Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first- or second-line treatment of advanced gastric and gastro-esophageal junction cancer

Cochrane Database of Systematic Reviews, 2019

Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitor... more Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immune checkpoint inhibitors for first-or second-line treatment of advanced gastric and gastro-esophageal junction cancer.

Research paper thumbnail of A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies

International Immunopharmacology

We aimed to evaluate immune-related adverse events occurring in clinical trials of anti-programme... more We aimed to evaluate immune-related adverse events occurring in clinical trials of anti-programmed cell death 1 (PD-1) drugs, compared with control treatments, including chemotherapy, targeted drugs, or placebo. Further we compared the occurrence of immune-related events in patients treated with different anti-PD-1 drugs. Data Sources: Randomized controlled trial (RCT) data were sourced from PubMed, Embase, and the Cochrane Central Register of Controlled Trials combined with clinicaltrials.gov. Methods: Randomized controlled trial of anti-PD-1 drugs compared with control treatments published between January 1, 1970 and March 1,2019, were searched and data on trial patient characteristics, and adverse events extracted, reviewed, and subjected to meta-analysis. Results: Eighteen Randomized controlled trials were included in our study. The Randomized controlled trials compared nivolumab (n ¼ 12), pembrolizumab (n ¼ 6), with chemotherapy (n ¼ 13), targeted drugs (n ¼ 2), or placebo (n ¼ 3). Compared with the control group, the risk of any immune-related adverse events in patients treated with anti-PD-1 drugs was increased (RR, 2.65; 95% confidence interval, 1.84-3.83; P < 0.00001). Of the immune-related adverse events, the risk rates of pneumonitis (